Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 0.8% – Here’s Why

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price shot up 0.8% during trading on Tuesday . The stock traded as high as $20.50 and last traded at $19.74. 558,870 shares traded hands during trading, a decline of 48% from the average session volume of 1,084,159 shares. The stock had previously closed at $19.58.

Analyst Ratings Changes

A number of equities analysts have commented on CAPR shares. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a report on Friday, September 20th. Maxim Group boosted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.60.

Capricor Therapeutics Stock Down 9.8 %

The stock has a 50-day moving average of $8.45 and a 200 day moving average of $6.36. The stock has a market cap of $591.29 million, a PE ratio of -22.11 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Research analysts forecast that Capricor Therapeutics Inc will post -1.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the purchase, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 12.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently modified their holdings of CAPR. Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after buying an additional 200,499 shares during the period. Renaissance Technologies LLC raised its stake in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 84,350 shares during the period. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the 2nd quarter worth approximately $426,000. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics during the 2nd quarter worth approximately $147,000. Finally, BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics in the 1st quarter valued at approximately $40,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.